A recent clinical trial has demonstrated that the combination of two medications—finerenone and empagliflozin—provides a more substantial benefit in reducing kidney damage in patients suffering from both chronic kidney disease (CKD) and type 2 diabetes, compared to using either drug alone.
The results come from the CONFIDENCE study, a research initiative funded by Bayer and registered under ClinicalTrials.gov number NCT05254002. The study focused on a key indicator of kidney health: the urinary albumin-to-creatinine ratio (UACR), which helps measure the amount of protein in the urine and signals the level of kidney damage.
Participants in the trial who received the combined therapy showed a significantly greater reduction in UACR than those who were treated with either finerenone or empagliflozin alone. This suggests a synergistic effect between the two drugs in providing renal protection.
Finerenone is a non-steroidal mineralocorticoid receptor antagonist designed to reduce inflammation and fibrosis in the kidneys, while empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that lowers blood sugar levels and has shown cardio-renal benefits.
Chronic kidney disease and type 2 diabetes are closely connected conditions that significantly increase the risk for cardiovascular disease and renal failure. Current treatment strategies include blood pressure control, glycemic control, and medications aimed at protecting kidney function.
The promising results from the CONFIDENCE trial indicate that using a combination of finerenone and empagliflozin might offer a new, more effective approach in managing and slowing the progression of kidney disease in patients with type 2 diabetes. Further peer-reviewed studies may help solidify their combined use in standard treatment guidelines.
Source: https:// – Courtesy of the original publisher.
